Literature DB >> 17947650

Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.

Jin-Sung Chung1, Irene Dougherty, Ponciano D Cruz, Kiyoshi Ariizumi.   

Abstract

Receptor-ligand interactions between APCs and T cells determine whether stimulation of the latter leads to activation or inhibition. Previously, we showed that dendritic cell-associated heparin sulfate proteoglycan-dependent integrin ligand (DC-HIL) on APC can inhibit T cell activation by binding an unknown ligand expressed on activated T cells. Because DC-HIL binds heparin/heparan sulfate and heparin blocks the inhibitory function of DC-HIL, we hypothesized that a heparin/heparan sulfate proteoglycan on activated T cells is the relevant ligand. Screening assays revealed that syndecan-4 (SD-4) is the sole heparan sulfate proteoglycan immunoprecipitated by DC-HIL from extracts of activated T cells and that blocking SD-4 abrogates binding of DC-HIL to activated T cells. Moreover, cell-bound SD-4 ligated by DC-HIL or cross-linked by anti-SD-4 Ab attenuated anti-CD3 responses, whereas knocked-down SD-4 expression led to enhanced T cell response to APC. Blockade of endogenous SD-4 using specific Ab or soluble SD-4 receptor led to augmented T cell reactions to syngeneic and allogeneic stimulation in vitro and exacerbated contact hypersensitivity responses in vivo. We conclude that SD-4 is the T cell ligand through which DC-HIL mediates its negative coregulatory function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947650     DOI: 10.4049/jimmunol.179.9.5778

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

2.  Generation and functional characterization of MDSC-like cells.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Jonas Schulte-Schrepping; Julia Friederike Andrea Wolff; Kathrin Klee; Thomas Ulas; Niklas Arndt Schmacke; Solveig Nora Daecke; Kati Riethausen; Joachim L Schultze; Peter Brossart
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

3.  DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.

Authors:  Mizuki Tomihari; Jin-Sung Chung; Hideo Akiyoshi; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

4.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 5.  Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  FASEB J       Date:  2020-05-23       Impact factor: 5.191

6.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

7.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

8.  The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Authors:  Jin-Sung Chung; Makoto Bonkobara; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

9.  Myeloid cells' evasion of melanoma immunity.

Authors:  Jun Wang; Lieping Chen
Journal:  J Invest Dermatol       Date:  2014-11       Impact factor: 8.551

10.  Syndecan-2 can promote clearance of T-cell receptor/CD3 from the cell surface.

Authors:  Xavier Rovira-Clavé; Maria Angulo-Ibáñez; Oriol Noguer; Enric Espel; Manuel Reina
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.